Microsoft: Earnings Estimates For Q1 2022

Microsoft (NASDAQ: MSFT) will be reporting its first quarter financial results on the 26th after the markets close. Analysts have a consensus $339.26 12-month price target on the company, via a total of 41 analysts, with 17 analysts having strong buy ratings. 22 analysts meanwhile have buy ratings, and 2 analysts have hold ratings on the company. The street high sits at a $384 price target, and the lowest target sits at $281.78.

25 analysts have revenue estimates for the first quarter. The mean revenue estimate between all 25 analysts is $44.97 billion; this number has been revised upwards from $41.90 billion at the start of April. The highest revenue estimate is $44.77 billion, while the lowest is $43.66 billion.

Onto EBITDA estimates, there are currently 4 analysts who have first-quarter EBITDA estimates. The mean is currently $22.28 billion, with this number having been revised upwards from $20.35 billion at the start of April. The street high estimate currently sits at $22.76 billion in EBITDA and the lowest is $21.56 billion.

Analysts estimate that quarterly earnings per share will come in at $2.07, with this number being revised upwards from $1.90 at the start of April. Street high is $2.17 and the lowest estimate is $2.03 per share for the quarter.


Information for this briefing was found via Edgar and Refinitiv. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

SSR Mining Walks Away From a World Class Gold-Copper Project

Why More Canadians Are Starting to Think About Leaving | Jesse Day

Instead of Waiting, This Gold Developer Went Bigger | Kenneth McLeod – Sonoro Gold

Recommended

Nord Drills 61,389 g/t Silver Over 0.30 Metres at Castle East

Mercado Minerals Targets District Scale Silver Play With San Dimas Land Grab

Related News

Eight Capital Initiates Coverage On Field Trip Health With $10.20 Price Target

Earlier this week, Eight Capital launched coverage on a basket of psychedelic companies. This comes...

Friday, September 17, 2021, 10:59:00 AM

Columbia Care Sees Consensus Price Target Rise To $14.70

On August 12, Columbia Care Inc. (CSE: CCHW) reported its second-quarter financial results, wherein the...

Wednesday, August 18, 2021, 10:09:00 AM

Sundial: Canaccord Drops Target To $0.50 Following Q1 Results

On Monday, Sundial Growers Inc. (Nasdaq: SNDL) reported its first quarter financial results. The company...

Wednesday, May 18, 2022, 03:44:00 PM

Haywood Lowers Tilray Price Target To $7.25

On January 10th, Tilray Inc (TSX: TLRY) reported their fiscal second-quarter financial results. The company...

Wednesday, January 12, 2022, 04:37:00 PM

Antibe Therapeutics: Canaccord Initiates Coverage, Issues $1.50 Price Target

Recently, Canaccord Genuity’s Tania Gonsalves initiated coverage on Antibe Therapeutics (TSXV: ATE), a biotechnology company...

Tuesday, August 18, 2020, 01:46:28 PM